|
Glypican-1 as a novel immunotherapeutic target in prostate cancer. |
|
|
Stock and Other Ownership Interests - NantWorks |
Research Funding - Minomic |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Minomic |
Patents, Royalties, Other Intellectual Property - Minomic (Inst) |
|
|
|
Stock and Other Ownership Interests - Minomic |
Patents, Royalties, Other Intellectual Property - Minomic (Inst) |
|
|
|
|
Stock and Other Ownership Interests - NantWorks |
|
Research Funding - NantWorks (Inst) |
Patents, Royalties, Other Intellectual Property - NantWorks (Inst) |
Travel, Accommodations, Expenses - NantWorks |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - NantWorks |
Consulting or Advisory Role - GenomeDx; Tokai Pharmaceuticals |
Research Funding - NantWorks |
Patents, Royalties, Other Intellectual Property - implantable nanotechnology for long term testosterone delivery functionalized fiducial marker for drug delivery |
Travel, Accommodations, Expenses - Tokai Pharmaceuticals |